Premium
Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with parkinson's disease
Author(s) -
Hauser Robert A.,
Olanow C. W.
Publication year - 1993
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870080417
Subject(s) - trihexyphenidyl , dyskinesia , medicine , discontinuation , levodopa , parkinson's disease , pramipexole , carbidopa , tardive dyskinesia , rotigotine , anesthesia , disease , psychiatry , schizophrenia (object oriented programming)
Dyskinesia is a common adverse effect complicating chronic dopaminergic therapy for Parkinson's disease. Movements are frequently choreic in nature and have been ascribed to overstimulation of “supersensitive” striatal postsynaptic dopamine receptors. Anticholinergic medications, despite some clinical efficacy in Parkinson's disease, have rarely been reported to cause dyskinesia. We report a patient with Parkinson's disease who developed orobuccal dyskinesia while being treated with trihexyphenidyl (Artane). Dyskinesia was observed following the introduction of trihexyphenidyl, resolved with its discontinuation, and reappeared with its reinstitution. Carbidopa‐levodopa (Sinemet) alone did not cause dyskinesia but augmented dyskinesia associated with trihexyphenidyl.